Open AccessMinimal change nephrotic syndrome due to certolizumab pegol, an anti-tumor necrosis factor-alpha monoclonal antibody for treatment of rheumatoid arthritis
Author(s) -
Masafumi Sugiyama,
Saki Okuda,
Yasuaki Hirooka
Publication year - 2022
Publication title -
rheumatology advances in practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.539
H-Index - 4
ISSN - 2514-1775
DOI - 10.1093/rap/rkac012
Subject(s) - medicine , certolizumab pegol , rheumatoid arthritis , monoclonal antibody , tumor necrosis factor alpha , nephrotic syndrome , rheumatoid factor , monoclonal , immunology , alpha (finance) , antibody , adalimumab , surgery , construct validity , patient satisfaction
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom